Jakob Nikolas Kather, Lara R. Heij, H. Grabsch, L. Kooreman, C. Loeffler, A. Echle, Jeremias Krause, H. Muti, J. Niehues, Kai A. J. Sommer, P. Bankhead, Jefree J. Schulte, N. Cipriani, R. D. Bülow, Nadina Ortiz-Brüchle, Akash Patnaik, Andrew Srisuwananukorn, H. Brenner, M. Hoffmeister, P. A. van den Brandt, D. Jäger, C. Trautwein, A. Pearson, Tom Luedde
2019.11.8Nature Cancer
tlooto Summary
It is shown that deep learning can consistently infer a wide range of genetic mutations, molecular tumor subtypes, gene expression signatures and standard pathology biomarkers directly from routine histology, potentially enabling point-of-care diagnostics for personalized cancer treatment.
Abstract
Molecular alterations in cancer can cause phenotypic changes in tumor cells and their microenvironment. Routine histopathology tissue slides, which are ubiquitously available, can reflect such morphological changes. Here, we show that deep learning can consistently infer a wide range of genetic mutations, molecular tumor subtypes, gene expression signatures and standard pathology biomarkers directly from routine histology. We developed, optimized, validated and publicly released a one-stop-shop workflow and applied it to tissue slides of more than 5,000 patients across multiple solid tumors. Our findings show that a single deep learning algorithm can be trained to predict a wide range of molecular alterations from routine, paraffin-embedded histology slides stained with hematoxylin and eosin. These predictions generalize to other populations and are spatially resolved. Our method can be implemented on mobile hardware, potentially enabling point-of-care diagnostics for personalized cancer treatment. More generally, this approach could elucidate and quantify genotype–phenotype links in cancer. Two papers by Kather and colleagues and Gerstung and colleagues develop workflows to predict a wide range of molecular alterations from pan-cancer digital pathology slides.
Citation format
KATHER, Jakob Nikolas, et al. Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2019, 1: 789–799.